{"id":"NCT04469465","sponsor":"Alexion Pharmaceuticals, Inc.","briefTitle":"Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)","officialTitle":"A Phase 3 Study of Danicopan (ALXN2040) as Add-on Therapy to a C5 Inhibitor (Eculizumab or Ravulizumab) in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Evident Extravascular Hemolysis (EVH)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-12-16","primaryCompletion":"2022-06-29","completion":"2024-01-16","firstPosted":"2020-07-14","resultsPosted":"2023-07-24","lastUpdate":"2025-05-04"},"enrollment":86,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Paroxysmal Nocturnal Hemoglobinuria"],"interventions":[{"type":"DRUG","name":"Danicopan","otherNames":["ALXN2040"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"C5 Inhibitor","otherNames":[]}],"arms":[{"label":"Danicopan + C5 Inhibitor","type":"EXPERIMENTAL"},{"label":"Placebo + C5 Inhibitor","type":"PLACEBO_COMPARATOR"}],"summary":"The main objective of this study is to evaluate the efficacy of danicopan as add-on therapy to a complement component 5 (C5) inhibitor (eculizumab or ravulizumab) in participants with PNH who have clinically evident EVH.","primaryOutcome":{"measure":"Change From Baseline in Hgb at Week 12","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"Danicopan (TP1)","deltaMin":29.4,"sd":2.107},{"arm":"Placebo (TP1)","deltaMin":4.96,"sd":3.128}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0007"},{"comp":"OG000 vs OG001","p":"0.0007"},{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":62,"countries":["United States","Brazil","Canada","Czechia","France","Germany","Greece","Israel","Italy","Japan","Malaysia","Netherlands","Poland","South Korea","Spain","Taiwan","Thailand","United Kingdom"]},"refs":{"pmids":["38030318","39700502"],"seeAlso":["https://library.ehaweb.org/eha/2019/24th/267447/peter.browett.a.phase.2.open","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&parentIdentifier=ALXN2040-PNH-301&attachmentIdentifier=5f3bdb66-e572-42a3-9aff-2abeca73c5f3&fileName=Synopsis_-_ALXN2040-PNH-301_Final_CSR_Redacted.pdf&versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":57},"commonTop":["Pyrexia","Headache","COVID-19","Diarrhoea","Nausea"]}}